Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Fabrinet (FN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Fabrinet — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.85 (market cap $4.49B), while Fabrinet trades at $480.82 (market cap $16.79B). The key difference: Fabrinet is far larger — about 3.7× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Fabrinet nearer its low. Which is the better fit depends on your goals.
| ACAD | FN | |
|---|---|---|
Market Cap | $4.49B | $16.79B |
Sector | Health | Technology |
52-Week High | $28.06 | $746.47 |
52-Week Low | $20.06 | $277.04 |
Enterprise Value | $3.69B | $15.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
FN trades at $500.75, up 0.23% with a bearish technical signal despite strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters with Q1 2026 EPS of $3.72 exceeding expectations. Analyst consensus remains strongly bullish with 75% buy ratings and a $733 price target, representing 46% upside potential from current levels. Recent news highlights FN's strategic position in AI optical supply chain with capacity expansion supporting multi-year growth visibility.
The outlook remains positive driven by AI infrastructure demand and strong execution, though premium valuation metrics (P/E 43.02) and technical bearish signals warrant caution. Key risks include datacom supply constraints and FX volatility, but robust revenue growth projections ($4.2B for 2026) and expanding margins support the bullish analyst stance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Fabrinet
Fabrinet provides advanced optical and electromechanical manufacturing services to original equipment manufacturers. It specializes in complex products for telecom, automotive, and medical industries.
Read more on FN →
